<DOC>
	<DOCNO>NCT02151409</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial develop complement system target monoclonal antibody ( mAb ) use treatment subject chronic autoimmune disease .</brief_summary>
	<brief_title>Dose-escalation Trial Anti-C5aR Antibody Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Informed consent obtain trialrelated activity ( Trialrelated activity procedure would perform normal management subject ) Body weight ( BW ) equal 110.0 kg Body Mass Index ( BMI ) 20.0 27.0 kg/m^2 , inclusive Good state health : evidenced medical history , physical examination result laboratory examination History know suspect cardiovascular disease include : supine systolic blood pressure ( BP ) equal 140 mmHg 90 mm Hg , diastolic BP oe equal 90 mm Hg 40 mm Hg , heart rate ( HR ) supine position 100 beats/minute 45 beats/minute Hepatic insufficiency : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) Upper Limit Normal ( ULN ) ( retesting permit within one week first test elevate 1.5 fold ULN ) Renal insufficiency : Serum creatinine ULN Positive humane immunodeficiency virus ( HIV ) ( test ) Positive hepatitis B ( HBV ) hepatitis C ( HCV ) ( test )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>